Literature DB >> 25201088

Asymptomatic carriage of Pneumocystis jirovecii and cytomegalovirus in lungs of immunocompetent patients.

Michal Shteinberg1, Pninit Shaked-Mishan, Amalia Kinarti, Amir Abramovitch, Anat Amital, Assaf Jacobi, Aharon E Kolup Feldmann, Maayan Shiner, Vladimir Gershtein, Gabriel Weber, Yochai Adir.   

Abstract

PURPOSE: Pneumocystis jirovecii (PCP) and cytomegalovirus (CMV) are opportunistic pathogens which cause lung infection in immunocompromised individuals. However, scarce data are available regarding the carriage of CMV or PCP in immunocompetent, non critically ill patients. The purpose of this study was to evaluate the prevalence of PCP and CMV in broncholaveolar lavage of adult immunocompetent, non critically ill patients.
METHODS: BAL fluids from immunocompetent patients who underwent bronchoscopy were analyzed by polymerase chain reaction (PCR) for CMV and PCP DNA. We tested CMV antibodies in serum. In patients with positive CMV DNA in lavage fluid, we further analyzed peripheral blood for the presence of CMV DNA.
RESULTS: Ninety three patients were included. We did not detect PCP DNA in BAL in any patient. CMV DNA was found in BAL of 5 of 86 CMV IgG positive patients (5.8 %). Patients who were positive for CMV did not differ from patients with negative PCR for CMV regarding demographic and clinical features.
CONCLUSION: We did not find PCP colonization in our cohort of patients. However, we found significant prevalence of CMV DNA in BAL from immunocompetent patients, with no evidence of acute CMV infection. This finding may represent colonization by CMV in immunocompetent, non-critically ill individuals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201088     DOI: 10.1007/s00408-014-9644-z

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  23 in total

1.  [OFEK virtual medical records: an evaluation of an integrated hospital-community system].

Authors:  Nurit Nirel; Bruce Rosen; Assaf Sharon; Orna Blondheim; Michael Sherf; Arnon D Cohen
Journal:  Harefuah       Date:  2011-02

2.  Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci.

Authors:  Enrique J Calderón; Laura Rivero; Nieves Respaldiza; Rubén Morilla; Marco A Montes-Cano; Vicente Friaza; Fernando Muñoz-Lobato; José M Varela; Francisco J Medrano; Carmen de la Horra
Journal:  Clin Infect Dis       Date:  2007-06-06       Impact factor: 9.079

3.  Outcomes of non-HIV-infected patients with Pneumocystis pneumonia and concomitant pulmonary cytomegalovirus infection.

Authors:  Tark Kim; Song Mi Moon; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim; Sang-Oh Lee
Journal:  Scand J Infect Dis       Date:  2012-01-21

4.  Immunological insights into the pathogenesis of active CMV infection in non-immunosuppressed critically ill patients.

Authors:  José Blanquer; Marifina Chilet; Isabel Benet; Gerardo Aguilar; Beatriz Muñoz-Cobo; Alexander Tellez; Elisa Costa; Dayana Bravo; David Navarro
Journal:  J Med Virol       Date:  2011-11       Impact factor: 2.327

5.  Human cytomegalovirus infections in nonimmunosuppressed critically ill patients.

Authors:  A Heininger; G Jahn; C Engel ; T Notheisen; K Unertl; K Hamprecht
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

6.  Cytomegalovirus as a primary pulmonary pathogen in AIDS.

Authors:  A B Waxman; S J Goldie; H Brett-Smith; R A Matthay
Journal:  Chest       Date:  1997-01       Impact factor: 9.410

7.  Bronchoalveolar lavage in immunocompromised patients with haematological malignancy--value of new microbiological methods.

Authors:  U Hohenthal; M Itälä; J Salonen; J Sipilä; K Rantakokko-Jalava; O Meurman; J Nikoskelainen; R Vainionpää; P Kotilainen
Journal:  Eur J Haematol       Date:  2005-03       Impact factor: 2.997

8.  Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study.

Authors:  N A Maskell; D J Waine; A Lindley; J C T Pepperell; A E Wakefield; R F Miller; R J O Davies
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

9.  Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population.

Authors:  Carolina A Ponce; Myriam Gallo; Rebeca Bustamante; Sergio L Vargas
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

10.  Pregnancy and asymptomatic carriage of Pneumocystis jiroveci.

Authors:  Sergio L Vargas; Carolina Angelica Ponce; Catherine Andrea Sanchez; Ana Victoria Ulloa; Rebeca Bustamante; Guido Juarez
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

View more
  3 in total

1.  Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.

Authors:  Waleed Elsegeiny; Taylor Eddens; Kong Chen; Jay K Kolls
Journal:  Infect Immun       Date:  2015-03-02       Impact factor: 3.441

2.  Colonization Density of the Upper Respiratory Tract as a Predictor of Pneumonia-Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Pneumocystis jirovecii.

Authors:  Daniel E Park; Henry C Baggett; Stephen R C Howie; Qiyuan Shi; Nora L Watson; W Abdullah Brooks; Maria Deloria Knoll; Laura L Hammitt; Karen L Kotloff; Orin S Levine; Shabir A Madhi; David R Murdoch; Katherine L O'Brien; J Anthony G Scott; Donald M Thea; Dilruba Ahmed; Martin Antonio; Vicky L Baillie; Andrea N DeLuca; Amanda J Driscoll; Wei Fu; Caroline W Gitahi; Emmanuel Olutunde; Melissa M Higdon; Lokman Hossain; Ruth A Karron; Abdoul Aziz Maiga; Susan A Maloney; David P Moore; Susan C Morpeth; John Mwaba; Musaku Mwenechanya; Christine Prosperi; Mamadou Sylla; Somsak Thamthitiwat; Scott L Zeger; Daniel R Feikin
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

Review 3.  The role of microRNAs in respiratory viral infection: friend or foe?

Authors:  Alireza Tahamtan; Christopher S Inchley; Mona Marzban; Masoumeh Tavakoli-Yaraki; Majid Teymoori-Rad; Britt Nakstad; Vahid Salimi
Journal:  Rev Med Virol       Date:  2016-07-04       Impact factor: 6.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.